class="post-template-default single single-post postid-25913 single-format-standard wp-custom-logo wp-embed-responsive link-highlight-style2 default-layout rishi-has-blocks rightsidebar rt-loading"itemscope="" itemtype="" data-link="type-2" data-forms="classic" data-prefix="single_blog_post" data-header="type-1:sticky" data-footer="type-1" itemscope="itemscope" itemtype="" >

Follicum is Back (by way of Coegin Pharma) | Hair Loss Cure 2020

I coated Follicum (Sweden) and its FOL-005 hair development peptide in eight posts between 2015 and 2021. The firm’s distinctive osteopontin based mostly method to treating hair loss was very attention-grabbing.

The identical method may stimulate scalp hair development and scale back physique hair development. And the identical know-how may doubtlessly deal with diabetes and irritation associated unintended effects.

Follicum’s common press releases, CEO Jan Alenfall’s displays, and the corporate’s speedy scientific trial development additionally impressed me. Their chief enterprise officer Gunnar Gårdemyr was additionally in common communication with me.

Follicum Past Clinical Trials

I coated each of Follicum’s previous scientific trial ends in 2017 and 2021, respectively.

  • Follicum’s Phase 1 scientific trial ends in 2017 had been constructive (8 p.c enhance in hair development), with an impact corresponding to that of Minoxidil. Moreover, security was not a difficulty, with no main unintended effects in trial pariticipants.
  • Unfortunately, whereas Follicum’s Phase 2 scientific trials of FOL-005 resulted in a 6.6 hair/cm2 enhance in hair development, this was deemed to be insignificant. These outcomes got here out in May 2021.

Thereafter, the corporate ceased additional improvement of FOL-005, and all of it appeared over for one more false flag operation. Or maybe not?

Merger and Acqusition by Coegin Pharma

In September 2021, Coegin Pharma merged with Follicum. This merger was confirmed as an acquisition in 2022.

In the primary of the 2 hyperlinks above, Coegin’s CEO Tore Duvold mentioned one thing of curiosity within the interview:

Question: “With regard to the hair loss project, which has recently been put on hold, how will it be handled once the companies merge”?

Answer: “Follicum announced that they have paused the hair loss project. In Coegin, we have strong capabilities in dermatology, and we will review and analyse the results before we make any conclusions”.

Follicum FOL-005 from Coegin Pharma.
Follicum FOL-005 scientific trial development standing. Source: Coegin Pharma.

Follicum Back within the News

  • In March, a Tweet from Coegin indicated that they had been assembly with potential companions for Follicum’s FOL-005.
  • Follicum was mentioned in February in an up to date article titled: “Could We See a New Dawn for Hair Loss Treatments?”. It summarizes the issues that the corporate confronted in making an attempt to carry FOL-005 to market after the unimpressive Phase 2 trial outcomes.
  • When going by Coegin Pharma’s web site, I discovered a extremely detailed comprehensive corportate presentation on Follicum and FOL-005. It was offered on the finish of 2022 by Coegin’s COO Kristian Lykke Fick.

Their tackle the previous trials is extra constructive. Key quote:

“FOL005 1.5% dose was on par with treatment effect reported for minoxidil and finasteride with a growth of 12 hairs/cm2 after 4 months of treatment. However, with more than 60% of subjects responding to treatment compared to competitors where 40% responders effect is previously documented after 4 months.”

Note that whereas Follicum’s old Swedish website remains to be lively, the main English site is now revamped. It has an expanded analysis part the place it covers FOL-005 in nice element. The firm plans to conduct varied new hair development associated scientific trials from 2023-2027. On their plans part they state the next:

“We believe there is a high likelihood of success based on the previous clinical data.”

Too dangerous concerning the new time-frame and the look forward to enterprise companions for funding. Otherwise, I’m not totally pessimistic about this product. I do really feel that it may well compete with Finasteride and Minoxidil when it comes to effectiveness, however by way of a very totally different mechanism of motion. And with few if any severe unintended effects.

Source by [author_name]

Leave a Reply

Your email address will not be published. Required fields are marked *